HomeCompareCSOL vs ABBV

CSOL vs ABBV: Dividend Comparison 2026

CSOL yields 6688.96% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSOL wins by $1062234097834972.00M in total portfolio value
10 years
CSOL
CSOL
● Live price
6688.96%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1062234097834972.13M
Annual income
$1,031,887,410,955,555,200,000.00
Full CSOL calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CSOL vs ABBV

📍 CSOL pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSOLABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSOL + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSOL pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSOL
Annual income on $10K today (after 15% tax)
$568,561.87/yr
After 10yr DRIP, annual income (after tax)
$877,104,299,312,221,900,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CSOL beats the other by $877,104,299,312,221,900,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSOL + ABBV for your $10,000?

CSOL: 50%ABBV: 50%
100% ABBV50/50100% CSOL
Portfolio after 10yr
$531117048917486.13M
Annual income
$515,943,705,477,777,600,000.00/yr
Blended yield
97.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CSOL
No analyst data
Altman Z
0.3
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSOL buys
0
ABBV buys
0
No recent congressional trades found for CSOL or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSOLABBV
Forward yield6688.96%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1062234097834972.13M$102.3K
Annual income after 10y$1,031,887,410,955,555,200,000.00$24,771.77
Total dividends collected$1060197980964661.88M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSOL vs ABBV ($10,000, DRIP)

YearCSOL PortfolioCSOL Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$679,596$668,896.32$11,550$430.00+$668.0KCSOL
2$43,211,232$42,484,063.46$13,472$627.96+$43.20MCSOL
3$2,570,808,801$2,524,572,782.97$15,906$926.08+$2570.79MCSOL
4$143,121,719,657$140,370,954,240.63$19,071$1,382.55+$143121.70MCSOL
5$7,456,610,117,399$7,303,469,877,365.59$23,302$2,095.81+$7456610.09MCSOL
6$363,594,623,628,531$355,616,050,802,913.70$29,150$3,237.93+$363594623.60MCSOL
7$16,594,962,640,350,284$16,205,916,393,067,752.00$37,536$5,121.41+$16594962640.31MCSOL
8$709,028,095,032,704,500$691,271,485,007,529,700.00$50,079$8,338.38+$709028095032.65MCSOL
9$28,361,389,606,931,763,000$27,602,729,545,246,765,000.00$69,753$14,065.80+$28361389606931.70MCSOL
10$1,062,234,097,834,972,200,000$1,031,887,410,955,555,200,000.00$102,337$24,771.77+$1062234097834972.00MCSOL

CSOL vs ABBV: Complete Analysis 2026

CSOLStock

China Solar & Clean Energy Solutions, Inc., through its subsidiaries, designs and provides integrated renewable energy solutions for industrial clients and real estate developers in China and internationally. The company offers evacuated tubular and flat plate solar water heaters; biomass stove; and spacing heating devices along with industrial waste heat recovery systems, including hot tube heat exchanger, high temperature hot air furnace, heat pipe evaporator, dust removal and desulfurization system, and constant pressure hot water boiler, as well as smokeless coal-fired boilers and bio-materials furnaces. It also provides industrial waste heat recovery systems, as well as heating products, such as heating pipes, heat exchangers, specialty heating pipes and tubes, high temperature hot blast stoves, heating filters, normal pressure water boilers, and radiators. In addition, the company offers densely covered regular tubular heaters; and sells spare parts for its products, as well as provides after-sales maintenance and repair services. China Solar & Clean Energy Solutions sells its products through a network of distributors, wholesalers, sales agents, and retailers. The company is based in Lake Mary, Florida.

Full CSOL Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CSOL vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSOL vs SCHDCSOL vs JEPICSOL vs OCSOL vs KOCSOL vs MAINCSOL vs JNJCSOL vs MRKCSOL vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.